GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharma Block Sciences (Nanjing) Inc (SZSE:300725) » Definitions » Piotroski F-Score

Pharma Block Sciences (Nanjing) (SZSE:300725) Piotroski F-Score : 6 (As of Apr. 16, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Pharma Block Sciences (Nanjing) Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma Block Sciences (Nanjing) has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Pharma Block Sciences (Nanjing)'s Piotroski F-Score or its related term are showing as below:

SZSE:300725' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 7
Current: 6

During the past 11 years, the highest Piotroski F-Score of Pharma Block Sciences (Nanjing) was 7. The lowest was 3. And the median was 5.


Pharma Block Sciences (Nanjing) Piotroski F-Score Historical Data

The historical data trend for Pharma Block Sciences (Nanjing)'s Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Block Sciences (Nanjing) Piotroski F-Score Chart

Pharma Block Sciences (Nanjing) Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 6.00 4.00 3.00 4.00

Pharma Block Sciences (Nanjing) Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 4.00 4.00 6.00 6.00

Competitive Comparison of Pharma Block Sciences (Nanjing)'s Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Pharma Block Sciences (Nanjing)'s Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Block Sciences (Nanjing)'s Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharma Block Sciences (Nanjing)'s Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Pharma Block Sciences (Nanjing)'s Piotroski F-Score falls into.


;
;

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 43.315 + 49.485 + 49.206 + 33.099 = ¥175 Mil.
Cash Flow from Operations was 98.27 + 55.33 + 81.746 + 51.802 = ¥287 Mil.
Revenue was 433.742 + 377.46 + 367.406 + 383.026 = ¥1,562 Mil.
Gross Profit was 179.784 + 161.15 + 143.311 + 143.566 = ¥628 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(5216.646 + 5104.032 + 4962.144 + 4726.199 + 4915.52) / 5 = ¥4984.9082 Mil.
Total Assets at the begining of this year (Sep23) was ¥5,217 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,139 Mil.
Total Current Assets was ¥2,689 Mil.
Total Current Liabilities was ¥806 Mil.
Net Income was 64.605 + 57.756 + 56.135 + 40.155 = ¥219 Mil.

Revenue was 409.998 + 383.441 + 460.617 + 447.404 = ¥1,701 Mil.
Gross Profit was 164.854 + 173.452 + 195.216 + 185.084 = ¥719 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(4955.54 + 4862.189 + 5004.414 + 5147.428 + 5216.646) / 5 = ¥5037.2434 Mil.
Total Assets at the begining of last year (Sep22) was ¥4,956 Mil.
Long-Term Debt & Capital Lease Obligation was ¥1,323 Mil.
Total Current Assets was ¥2,910 Mil.
Total Current Liabilities was ¥1,011 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma Block Sciences (Nanjing)'s current Net Income (TTM) was 175. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Pharma Block Sciences (Nanjing)'s current Cash Flow from Operations (TTM) was 287. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=175.105/5216.646
=0.03356659

ROA (Last Year)=Net Income/Total Assets (Sep22)
=218.651/4955.54
=0.04412254

Pharma Block Sciences (Nanjing)'s return on assets of this year was 0.03356659. Pharma Block Sciences (Nanjing)'s return on assets of last year was 0.04412254. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Pharma Block Sciences (Nanjing)'s current Net Income (TTM) was 175. Pharma Block Sciences (Nanjing)'s current Cash Flow from Operations (TTM) was 287. ==> 287 > 175 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=1139.449/4984.9082
=0.22857974

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=1323.041/5037.2434
=0.26265179

Pharma Block Sciences (Nanjing)'s gearing of this year was 0.22857974. Pharma Block Sciences (Nanjing)'s gearing of last year was 0.26265179. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=2688.916/806.342
=3.33470909

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=2910.14/1011.294
=2.87763993

Pharma Block Sciences (Nanjing)'s current ratio of this year was 3.33470909. Pharma Block Sciences (Nanjing)'s current ratio of last year was 2.87763993. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Pharma Block Sciences (Nanjing)'s number of shares in issue this year was 201.933. Pharma Block Sciences (Nanjing)'s number of shares in issue last year was 202.204. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=627.811/1561.634
=0.40202186

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=718.606/1701.46
=0.42234669

Pharma Block Sciences (Nanjing)'s gross margin of this year was 0.40202186. Pharma Block Sciences (Nanjing)'s gross margin of last year was 0.42234669. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=1561.634/5216.646
=0.29935595

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=1701.46/4955.54
=0.34334502

Pharma Block Sciences (Nanjing)'s asset turnover of this year was 0.29935595. Pharma Block Sciences (Nanjing)'s asset turnover of last year was 0.34334502. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+1+1+1+1+0+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Pharma Block Sciences (Nanjing) has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Pharma Block Sciences (Nanjing)  (SZSE:300725) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Pharma Block Sciences (Nanjing) Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Pharma Block Sciences (Nanjing)'s Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Block Sciences (Nanjing) Business Description

Traded in Other Exchanges
N/A
Address
10 Xuefu Road, Nanjing High-tech Industrial Development Zone, Jiangsu, Nanjing, 210032, CHN, 210032
Pharma Block Sciences (Nanjing) Inc is a chemistry products and services provider through the pharmaceutical research and development process. Its core business activities include pilot plant and commercial manufacturing of key intermediates and active pharmaceutical ingredient, process development, custom synthesis and building blocks.
Executives
Yang Min Min Directors, executives
Directors, executives
Chen La Mei Executives
Wu Xi Han Director
Executives
Directors, executives
Luo Fei Supervisors

Pharma Block Sciences (Nanjing) Headlines

No Headlines